Rodolfo J. Galindo MD, FACEAssociate Professor of Medicine, Miller School of Medicine, University of Miami; Director, Comprehensive Diabetes Center, Lennar Medical Foundation, UM Health System; Director, Diabetes Management, Jackson Health System, Miami, Florida
Dr. Rodolfo J. Galindo graduated from the Institute of Medical Sciences at the University of Havana in 2005. Dr. Galindo completed his Internal Medicine residency and Endocrinology fellowship at the Albert Einstein College of Medicine, and North Shore University Hospital, in New York. After completing his fellowship, Dr. Galindo joined the faculty, as an Assistant Professor, of the Mount Sinai School of Medicine, where he was the Director of the Inpatient Diabetes Service. In 2017, Dr. Galindo joined the faculty of Emory University, to work with his mentor, Dr. Guillermo E. Umpierrez, on clinical investigation in diabetes and obesity. Currently, Dr. Galindo is currently an Associate Professor of Medicine at the University of Miami, and Director of the Comprehensive Diabetes Center of UHealth and the Director of Diabetes Management for Jackson Health System, in Miami.
His clinical and research areas of interest included management of diabetes, obesity and CKD, using diabetes technology. His research program is supported by the NIH, NIDDK, foundations and industry. His works has been published in high-impact journals, including Endocrine Reviews, Diabetes Care, JAMA, BMJ Open Diabetes Care, Diabetes Research and Clinical Practice, Endocrine Practice, Journal of Clinical Endocrinology and Metabolism, Diabetes, Obesity & Metabolism, Obesity, Journal of Diabetes Science and Technology, Journal of the American Surgical Society, etc. Dr. Galindo has also served as member and author of national and international diabetes guidelines, including the Consensus Statement on the Use of Diabetes Technology in the Hospital (sponsored by the Diabetes Technology Society in 2020), the AACE Diabetes Mellitus Comprehensive Care Plan in 2022 and AACE Algorithm for the Management of Type 2 Diabetes in 2023 (sponsored by the American Association of Clinical Endocrinologists).
Dr. Galindo is currently a member of the taskforce to update the Diabetes Ketoacidosis guidelines (sponsored by the American Diabetes Association, 2023-2024), and also a member/writing author of the Standard of Care for Diabetes guidelines from ADA 2024.
Dr. Galindo is partly supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH) under Award Numbers 2P30DK111024 (RJG) and K23DK123384. He has received unrestricted research support (to Emory University) from Novo Nordisk, Dexcom and Eli Lilly and consulting/advisory/honoraria fees from Abott Diabetes Care, Dexcom Eli Lilly, Novo Nordisk, Boehringer-Ingelheim, Bayer, and Weight Watchers, outside the scope of this work.